ERYTECH Announces Positive DSMB Review of its Phase IIb Study in Acute Myeloid Leukemia

12-11-2013 Business Wire HealthComments (0)

Erytech PharmaPharmaceutical

ERYTECH Pharma (Paris:ERYP) (NYSE Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces that an independent Data and Safety Monitoring Board (DSMB) completed its first assessment of the company’s Phase IIb study in Acute Myeloid Leukemia (AML) study and unanimously recommended continuation of the trial withou

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top